Lenacapavir: Twice-Yearly Injection Shows High Efficacy in HIV Prevention
• Lenacapavir, administered as a twice-yearly injection, demonstrates a 96% reduction in HIV infection risk compared to background incidence.
• Clinical trials reveal lenacapavir's superior efficacy over daily oral PrEP medications like Truvada, particularly addressing adherence challenges.
• The FDA is reviewing lenacapavir for potential approval in 2025, offering a promising long-acting option for HIV prevention.
• Global health experts emphasize the importance of equitable access and affordability to ensure widespread adoption of lenacapavir.
Novel Antibody-like Molecule Shows Promise for Broad-Spectrum Malaria Therapy
• Researchers have discovered WD34, a novel antibody-like molecule, that inhibits malaria parasite infection at various disease stages.
• WD34 binds to the AMA1 protein, common across malaria species, blocking the mechanism parasites use to enter liver and red blood cells.
• Pre-clinical trials suggest WD34 could protect against multiple malaria parasite species, offering a potential broad-spectrum therapeutic option.
• The discovery opens new avenues for developing a universal malaria vaccine, addressing drug resistance and treatment failures.
© Copyright 2025. All Rights Reserved by MedPath